Cardiovascular Devices are used in treating diseases related to the heart and the circulatory system. Structural Heart Occlusion Devices are used to close defects in heart, reducing the risk of stroke and treating congenital heart defects. GlobalData uses proprietary data and analytics to provide a comprehensive report on the structural heart occlusion devices market in Norway. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the structural heart occlusion devices market in Norway was Abbott Laboratories followed by W. L. Gore & Associates, Boston Scientific, AtriCure, Occlutech, pfm medical and LifeTech Scientific.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
Structural Heart Occlusion Devices provide minimally invasive treatment options for the closure of congenital heart defects and for stroke risk reduction. The closure interventions are typically performed through a transcatheter approach, which eliminates the need for open heart surgery, enabling faster recovery times. The structural heart occlusion device consists of Atrial Septal Defect Occluders, Ventricular Septal Defect Occluders, Patent Ductus Arteriosus Closure Devices, Patent Foramen Ovale Closure Devices and Left Atrial Appendage Closure Devices.
The structural heart occlusion devices market in Norway can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size structural heart occlusion devices in Norway, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.
